Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural m...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
7 Oct 2019
Checkmate 227: Final analysis for the non small cell lung cancer trial
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
Checkmate 227: Final analysis for the non small cell lung cancer trial ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )
4 Oct 2019
Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain
Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC ( Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain )
4 Oct 2019
AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours
Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA
AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours ( Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA )
4 Oct 2019
Blood first assay screening in patients with ALK positive NSCLC
Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA
Blood first assay screening in patients with ALK positive NSCLC ( Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA )
4 Oct 2019
Holistic management of patients with ALK-positive NSCLC
Rachel Thomas and Jackie Fenemore
Holistic management of patients with ALK-positive NSCLC ( Rachel Thomas and Jackie Fenemore )
3 Oct 2019
Precision medicine in ALK-positive NSCLC: Results from the BFAST trial
Prof Solange Peters and Prof Tony Mok
Precision medicine in ALK-positive NSCLC: Results from the BFAST trial ( Prof Solange Peters and Prof Tony Mok )
3 Oct 2019
Comment: Nivolumab plus ipilimumab combination for advanced NSCLC
Dr Marina Garassino - National Tumor Institute, Milan, Italy
Comment: Nivolumab plus ipilimumab combination for advanced NSCLC ( Dr Marina Garassino - National Tumor Institute, Milan, Italy )
28 Sep 2019
Comment: Osimertinib for EGFR-mutation positive NSCLC
Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain
Comment: Osimertinib for EGFR-mutation positive NSCLC ( Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain )
28 Sep 2019
Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanc...
Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switze...
Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC ( Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )
28 Sep 2019
Front-line osimertinib significantly lengthens overall survival in EGFR-mutation...
Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, ...
Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )
28 Sep 2019